Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 2500
Journal of Novel Physiotherapies received 2500 citations as per Google Scholar report
Journal of Novel Physiotherapies peer review process verified at publons
Indexed In
- Index Copernicus
- Google Scholar
- Open J Gate
- Genamics JournalSeek
- Academic Keys
- SafetyLit
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
Neuropsychiatric drugs
Neuropsychiatric drugs are medications designed to treat disorders that affect both neurological and psychiatric functions. These drugs are used to manage a variety of conditions, including depression, anxiety, schizophrenia, bipolar disorder, and neurodegenerative diseases. They work by targeting neurotransmitter systems in the brain, which play a crucial role in regulating mood, cognition, and behavior. For instance, antidepressants such as Selective Serotonin Reuptake Inhibitors (SSRIs) enhance serotonin levels to improve mood, while antipsychotics can modulate dopamine activity to manage symptoms of psychosis. The development and use of neuropsychiatric drugs require careful consideration of efficacy, side effects, and interactions with other medications. Ongoing research aims to refine these treatments, enhance their effectiveness, and minimize adverse effects, with the ultimate goal of improving mental health outcomes and quality of life for individuals with complex neuropsychiatric conditions.
Neuropsychiatric drugs
Expert PPTs
- J. Lucas Koberda
Electrical Brain Imaging
PPT Version | PDF Version - Srinivasan Shanmugam
Lipid Based Oral Drug Delivery System (LBODDS)
PPT Version | PDF Version - Ioan Magyar
Introduction to Clinical Pharmacology
PPT Version | PDF Version
Speaker PPTs
- Barbara Klajnert-Maculewicz
Sugar-modified PPI dendrimers as carriers of anti-leukemia drugs
PPT Version | PDF Version - Rinat Islamov
Pharmacokinetics (PK) of anti-tuberculosis drug (FS-1) on healthy volunteers: results from the phase I trial
PPT Version | PDF Version - Almas Okassov
Chemical modification of anticancer Parasporins for decreasing of their toxicity
PPT Version | PDF Version - Sevgi Gungor
Micelles as nanosized carriers for skin delivery of drugs
PPT Version | PDF Version - Ru Band Lu
Anti-Inflammation and neuroprotective drugs benefit the treatment of heroin dependent patients
PPT Version | PDF Version - Anita Nair
BCS-Based Biowaivers: Which Drugs are Eligible?
PPT Version | PDF Version - Richard A. Kenley
Equilibrium binding interactions between lotrafilcon a soft contact lenses and the two prostaglandin anti-glaucoma drugs Bimatoprost and Tafluprost
PPT Version | PDF Version - Elena Gavrilova
Application of drugs based on release-active antibodies as immunotherapy agents
PPT Version | PDF Version - Jung-Joon Min
Bacteria-mediated expression of cargo drugs and reporter gene for cancer-specific theranostics
| PDF Version - Vladimir Torchilin
Stimuli-sensitive combination nanopreparations of siRNA and chemotherapeutic drugs to treat multidrug resistant cancer
PPT Version | PDF Version - Grace London
Development of aptamer based HIV-1 entry inhibitor prophylactic drugs
PPT Version | PDF Version - Aina Westrheim Ravna
Novel sildenafil analogues: possible drugs for increased sensitivity to chemotherapeutic agents
PPT Version | PDF Version